Factor VIII (F8) Mouse Monoclonal Antibody [Clone ID: 2A5]

CAT#: BM407

Factor VIII (F8) mouse monoclonal antibody, clone 2A5, Purified

Specifications

Product Data

• Clone Name: 2A5
• Applications: ELISA
• Recommended Dilution: ELISA.
• Reactivities: Human
• Host: Mouse
• Isotype: IgG2a
• Clonality: Monoclonal
• Immunogen: Purified Human Factor VIII
• Specificity: This antibody recognizes the 83 kDa light chain of Factor VIII. It does not cross-react with Von Willebrand factor.
• Formulation: PBS, pH 7.2 containing 0.09% Sodium Azide as preservative
  State: Purified
  State: Liquid purified IgG fraction
• Concentration: lot specific
• Purification: Affinity Chromatography on Protein A
• Conjugation: Unconjugated
• Storage: Store the antibody undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer.
  Avoid repeated freezing and thawing.
• Stability: Shelf life: one year from despatch.
• Gene Name: coagulation factor VIII
• Database Link:
  Entrez Gene 2157 Human
  UniProt ID P00451
• Background: Factor VIII, along with calcium and phospholipid, acts as a cofactor for factor IXa when it converts factor X to the activated form, factor Xa. It is an extracellular factor. Defects in F8 are the cause of hemophilia A (HEMA). HEMA is a common recessive X linked coagulation disorder. The frequency of hemophilia A is 1-2 in 10,000 male births in all ethnic groups. About 50% of patients have severe hemophilia A with F8C activity less than 1% of normal; they have frequent spontaneous bleeding into joints, muscles and internal organs. Moderately severe hemophilia A occurs in about 10% of patients; F8C activity is 2-5% of normal, and there is bleeding after minor trauma. Mild hemophilia A, which occurs in 30-40% of patients, is associated with F8C activity of 5-30% and bleeding occurs only after significant trauma or surgery. Of particular interest for the understanding of the function of F8C is the category of CRM (cross-reacting material) positive patients (approximately 5%) that have considerable amount of F8C in their plasma (at least 30% of normal), but the protein is nonfunctional; i.e., the F8C activity is much less than the plasma protein level. CRM reduced is another category of patients in which the F8C antigen and activity are reduced to approximately the same level. Most mutations are CRM negative, and probably affect the folding and stability of the protein.
• Synonyms: Procoagulant component, Antihemophilic factor, F8C, AHF